I've run the numbers through my "Eazy Bake Number Cruncher" (patent pending) and came up about a $16.40 pps based on revenue only for COVID sales in 2020.
(Mileage may vary, objects appear closer in mirror, contents of cup are hot, etc...)
I figure dilution by the end of the calendar year due to warrants and increase in available shares will be about 530M shares (hopefully worst case).
Right now in the US there are roughly 2.3M people sick w/COVID and about 17% require hospitalization...or about 390,000 M2M and S2C. That rationalizes the 375,000 patients @ 4 vials/patient.
For gits and shiggles, let's say that 375K patients were sick enough to be treated with Leronlimab; and/or, additional people from outside the US come here to be treated to exhaust 1.2M vial supply for 2020.
If CytoDyn sells all 1.2M vials @ $750/dose* with COGs $31M to net $870M profit. That's $1.64 net revenue per share.
(* See my earlier post calculating/guessing at CytoDyn's selling cost.)
Put a P/E of 10 on top and you get a share price $16.40.
Sentiment and panic buying throws those numbers to the wind.
Not a bad kickstart to begin the year selling for HIV-1 near Dec/Jan and potential other conditions during 2021.
Can't make enough Leronlimab fast enough.
News 
Market Data 
Discover 
AI
